Cargando…

Ayurvedic formulations: Potential COVID-19 therapeutics?

Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahaboob Ali, Anees Ahmed, Bugarcic, Andrea, Naumovski, Nenad, Ghildyal, Reena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020642/
https://www.ncbi.nlm.nih.gov/pubmed/35474908
http://dx.doi.org/10.1016/j.phyplu.2022.100286
_version_ 1784689596164997120
author Mahaboob Ali, Anees Ahmed
Bugarcic, Andrea
Naumovski, Nenad
Ghildyal, Reena
author_facet Mahaboob Ali, Anees Ahmed
Bugarcic, Andrea
Naumovski, Nenad
Ghildyal, Reena
author_sort Mahaboob Ali, Anees Ahmed
collection PubMed
description Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practitioners with minimal adverse reactions and intense research efforts are currently under way to develop some of these formulations for COVID-19 treatment. Methods: Literature search for in silico, in vitro, in vivo, and clinical studies on the topic of Ayurvedic formulations for potential COVID-19 treatment, in order to present the current state of current knowledge by integrating information across all systems. Results: The search yielded 20 peer reviewed articles on in silico studies examining the interaction of phytoconstituents of popular Ayurvedic formulations with SARS-CoV-2 components and its receptors; five articles on preclinical investigations of the ability of selected Ayurvedic formulations to inhibit functions of SARS-CoV-2 proteins; and 51 completed clinical trials on the efficacy of using Ayurvedic formulations for treatment of mild to moderate COVID-19. Clinical data was available from 17 of the 51 trials. There was a considerable overlap between formulations used in the in silico studies and the clinical trials. This finding was unexpected as there is no clearly stated alignment between studies and the traditional pathway to drug discovery– basic discovery leading to in vitro and in vivo proof of concept, followed by validation in clinical trials. This was further demonstrated in the majority of the in silico studies where focus was on potential antiviral mechanisms, while the clinical trials were focused on patient recovery using oral treatments. In all 17 clinical trials where data was available, Ayurvedic treatments lead to a shorter period to recovery in participants with COVID-19. Conclusion: The most commonly used Ayurvedic treatments for management of respiratory symptoms associated with SARS-CoV-2 infection appear to have prophylactic and/or therapeutic properties. It would be of particular interest to assess synergistic and concomitant systemic effects and antiviral activities of individual phytoconstituents and their combinations in the Ayurvedic treatments.
format Online
Article
Text
id pubmed-9020642
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-90206422022-04-21 Ayurvedic formulations: Potential COVID-19 therapeutics? Mahaboob Ali, Anees Ahmed Bugarcic, Andrea Naumovski, Nenad Ghildyal, Reena Phytomed Plus Article Background: While Molnupiravir and Paxlovid have recently been approved for use in some countries, there are no widely available treatments for COVID-19, the disease caused by SARS-CoV-2 infection. Herbal extracts have been used to treat respiratory clinical indications by Ayurvedic medicine practitioners with minimal adverse reactions and intense research efforts are currently under way to develop some of these formulations for COVID-19 treatment. Methods: Literature search for in silico, in vitro, in vivo, and clinical studies on the topic of Ayurvedic formulations for potential COVID-19 treatment, in order to present the current state of current knowledge by integrating information across all systems. Results: The search yielded 20 peer reviewed articles on in silico studies examining the interaction of phytoconstituents of popular Ayurvedic formulations with SARS-CoV-2 components and its receptors; five articles on preclinical investigations of the ability of selected Ayurvedic formulations to inhibit functions of SARS-CoV-2 proteins; and 51 completed clinical trials on the efficacy of using Ayurvedic formulations for treatment of mild to moderate COVID-19. Clinical data was available from 17 of the 51 trials. There was a considerable overlap between formulations used in the in silico studies and the clinical trials. This finding was unexpected as there is no clearly stated alignment between studies and the traditional pathway to drug discovery– basic discovery leading to in vitro and in vivo proof of concept, followed by validation in clinical trials. This was further demonstrated in the majority of the in silico studies where focus was on potential antiviral mechanisms, while the clinical trials were focused on patient recovery using oral treatments. In all 17 clinical trials where data was available, Ayurvedic treatments lead to a shorter period to recovery in participants with COVID-19. Conclusion: The most commonly used Ayurvedic treatments for management of respiratory symptoms associated with SARS-CoV-2 infection appear to have prophylactic and/or therapeutic properties. It would be of particular interest to assess synergistic and concomitant systemic effects and antiviral activities of individual phytoconstituents and their combinations in the Ayurvedic treatments. The Author(s). Published by Elsevier B.V. 2022-08 2022-04-20 /pmc/articles/PMC9020642/ /pubmed/35474908 http://dx.doi.org/10.1016/j.phyplu.2022.100286 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Mahaboob Ali, Anees Ahmed
Bugarcic, Andrea
Naumovski, Nenad
Ghildyal, Reena
Ayurvedic formulations: Potential COVID-19 therapeutics?
title Ayurvedic formulations: Potential COVID-19 therapeutics?
title_full Ayurvedic formulations: Potential COVID-19 therapeutics?
title_fullStr Ayurvedic formulations: Potential COVID-19 therapeutics?
title_full_unstemmed Ayurvedic formulations: Potential COVID-19 therapeutics?
title_short Ayurvedic formulations: Potential COVID-19 therapeutics?
title_sort ayurvedic formulations: potential covid-19 therapeutics?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020642/
https://www.ncbi.nlm.nih.gov/pubmed/35474908
http://dx.doi.org/10.1016/j.phyplu.2022.100286
work_keys_str_mv AT mahaboobalianeesahmed ayurvedicformulationspotentialcovid19therapeutics
AT bugarcicandrea ayurvedicformulationspotentialcovid19therapeutics
AT naumovskinenad ayurvedicformulationspotentialcovid19therapeutics
AT ghildyalreena ayurvedicformulationspotentialcovid19therapeutics